Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection
Childhood acquired chronic hepatitis B is associated with a significant lifetime risk of developing cirrhosis or hepatocellular carcinoma. Our objective in this study was to report retrospectively the response to treatment with Entecavir in 8 children with chronic hepatitis B followed at the King Ab...
Saved in:
Published in | Arab journal of gastroenterology Vol. 13; no. 2; pp. 41 - 44 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Egypt
01.06.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Childhood acquired chronic hepatitis B is associated with a significant lifetime risk of developing cirrhosis or hepatocellular carcinoma. Our objective in this study was to report retrospectively the response to treatment with Entecavir in 8 children with chronic hepatitis B followed at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
This study is an observational hospital based chart review of children and adolescents with chronic hepatitis B treated with entecavir at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia in the period between June 2007 and July 2011.
Half of the studied group was males, and the median age at the time of treatment was 4.8 years (range, 2.6-15). All subjects displayed infection with HBV genotype D and all were HBeAg positive. Half of the patients had been previously treated with lamivudine, while the remaining half was treatment naïve patients. The mean ALT±SD was 84.9±34.7IU/L (range, 46-133) and the mean HBV DNA was 5.01×10(8)±5.7×10(8) IU/mL (range, 5.5×10(7)-1.3×10(9)). Patients were treated with a daily oral dose of 0.5mg entecavir, and the mean duration of treatment was 23.8±11.9 months, (range 14.9-44.7 months). HBV DNA suppression of more than 2 log(10) was achieved in all patients. HBV DNA was undetected in 37.5%, with ALT normalization in 87.5% and lastly HBeAg seroconversion and loss occurred in 37.5%. No adverse side effects were observed during the treatment with entecavir.
We conclude from this limited data that 37.5% of children treated with entecavir achieved HBeAg loss and seroconversion with no side effects observed during treatment period, however long term safety and efficacy in children should be demonstrated through a multicenter study, enrolling large number of patients. |
---|---|
AbstractList | Childhood acquired chronic hepatitis B is associated with a significant lifetime risk of developing cirrhosis or hepatocellular carcinoma. Our objective in this study was to report retrospectively the response to treatment with Entecavir in 8 children with chronic hepatitis B followed at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
This study is an observational hospital based chart review of children and adolescents with chronic hepatitis B treated with entecavir at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia in the period between June 2007 and July 2011.
Half of the studied group was males, and the median age at the time of treatment was 4.8 years (range, 2.6-15). All subjects displayed infection with HBV genotype D and all were HBeAg positive. Half of the patients had been previously treated with lamivudine, while the remaining half was treatment naïve patients. The mean ALT±SD was 84.9±34.7IU/L (range, 46-133) and the mean HBV DNA was 5.01×10(8)±5.7×10(8) IU/mL (range, 5.5×10(7)-1.3×10(9)). Patients were treated with a daily oral dose of 0.5mg entecavir, and the mean duration of treatment was 23.8±11.9 months, (range 14.9-44.7 months). HBV DNA suppression of more than 2 log(10) was achieved in all patients. HBV DNA was undetected in 37.5%, with ALT normalization in 87.5% and lastly HBeAg seroconversion and loss occurred in 37.5%. No adverse side effects were observed during the treatment with entecavir.
We conclude from this limited data that 37.5% of children treated with entecavir achieved HBeAg loss and seroconversion with no side effects observed during treatment period, however long term safety and efficacy in children should be demonstrated through a multicenter study, enrolling large number of patients. BACKGROUND AND STUDY AIMSChildhood acquired chronic hepatitis B is associated with a significant lifetime risk of developing cirrhosis or hepatocellular carcinoma. Our objective in this study was to report retrospectively the response to treatment with Entecavir in 8 children with chronic hepatitis B followed at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia.PATIENTS AND METHODSThis study is an observational hospital based chart review of children and adolescents with chronic hepatitis B treated with entecavir at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia in the period between June 2007 and July 2011.RESULTSHalf of the studied group was males, and the median age at the time of treatment was 4.8 years (range, 2.6-15). All subjects displayed infection with HBV genotype D and all were HBeAg positive. Half of the patients had been previously treated with lamivudine, while the remaining half was treatment naïve patients. The mean ALT±SD was 84.9±34.7IU/L (range, 46-133) and the mean HBV DNA was 5.01×10(8)±5.7×10(8) IU/mL (range, 5.5×10(7)-1.3×10(9)). Patients were treated with a daily oral dose of 0.5mg entecavir, and the mean duration of treatment was 23.8±11.9 months, (range 14.9-44.7 months). HBV DNA suppression of more than 2 log(10) was achieved in all patients. HBV DNA was undetected in 37.5%, with ALT normalization in 87.5% and lastly HBeAg seroconversion and loss occurred in 37.5%. No adverse side effects were observed during the treatment with entecavir.CONCLUSIONWe conclude from this limited data that 37.5% of children treated with entecavir achieved HBeAg loss and seroconversion with no side effects observed during treatment period, however long term safety and efficacy in children should be demonstrated through a multicenter study, enrolling large number of patients. |
Author | Saadah, Omar I Bin-Talib, Yagoub Al-Harthi, Sameer Sindi, Haifa H Al-Mughales, Jamil |
Author_xml | – sequence: 1 givenname: Omar I surname: Saadah fullname: Saadah, Omar I email: saadaho@hotmail.com organization: Department of Paediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. saadaho@hotmail.com – sequence: 2 givenname: Haifa H surname: Sindi fullname: Sindi, Haifa H – sequence: 3 givenname: Yagoub surname: Bin-Talib fullname: Bin-Talib, Yagoub – sequence: 4 givenname: Sameer surname: Al-Harthi fullname: Al-Harthi, Sameer – sequence: 5 givenname: Jamil surname: Al-Mughales fullname: Al-Mughales, Jamil |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22980589$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kMtOwzAURC0Eog_4ADbISzYJ107jxxJQeUiV2JR15Dg3ravEKbYL6t8TRFmNNHM0Gs2MnPvBIyE3DHIGTNzvcrPb5BwYz2GRA7AzMuWgIeOFkhMyi3EHIARjcEkmnGsFpdJTsl76hNZ8uUBTQJN69IkOLbVb1zUBPeUZE_SIJsRf22yQfru0HfMweGfpFvcmueQifaTOt2iTG_wVuWhNF_H6pHPy8bxcP71mq_eXt6eHVbZnXKSsaXgrCmVB6xoZV0w2jWyk4KgKq8etSjGNCwmqlJbVtQAphRTAJXBdMl7Myd1f7z4MnweMqepdtNh1xuNwiBWDxdhdllKO6O0JPdQ9NtU-uN6EY_X_RPEDAnJeTg |
ContentType | Journal Article |
Copyright | Copyright © 2012 Arab Journal of Gastroenterology. Published by Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: Copyright © 2012 Arab Journal of Gastroenterology. Published by Elsevier Ltd. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.ajg.2012.04.001 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2090-2387 |
EndPage | 44 |
ExternalDocumentID | 22980589 |
Genre | Journal Article |
GroupedDBID | --- --K --M .~1 0R~ 1B1 1~. 1~5 4.4 457 4G. 5VS 6J9 7-5 71M 8P~ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAXKI AAXUO ABBQC ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AFJKZ AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV CGR CUY CVF D1A EBS ECM EFJIC EIF EJD EP3 FDB FEDTE FIRID FNPLU FYGXN GBLVA GX1 HVGLF HZ~ J1W KOM M41 MO0 N9A NPM O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 RIG ROL SDF SEL SES SPCBC SSH SSZ T5K ~G- 7X8 |
ID | FETCH-LOGICAL-p126t-dd2f638c099be12817dd7d762e83c96618819e470857c1bb60776760270295123 |
IngestDate | Sat Aug 17 02:29:55 EDT 2024 Sat Sep 28 08:05:37 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | Copyright © 2012 Arab Journal of Gastroenterology. Published by Elsevier Ltd. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p126t-dd2f638c099be12817dd7d762e83c96618819e470857c1bb60776760270295123 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 22980589 |
PQID | 1040995577 |
PQPubID | 23479 |
PageCount | 4 |
ParticipantIDs | proquest_miscellaneous_1040995577 pubmed_primary_22980589 |
PublicationCentury | 2000 |
PublicationDate | 2012-Jun 20120601 |
PublicationDateYYYYMMDD | 2012-06-01 |
PublicationDate_xml | – month: 06 year: 2012 text: 2012-Jun |
PublicationDecade | 2010 |
PublicationPlace | Egypt |
PublicationPlace_xml | – name: Egypt |
PublicationTitle | Arab journal of gastroenterology |
PublicationTitleAlternate | Arab J Gastroenterol |
PublicationYear | 2012 |
SSID | ssj0066110 |
Score | 1.9501086 |
Snippet | Childhood acquired chronic hepatitis B is associated with a significant lifetime risk of developing cirrhosis or hepatocellular carcinoma. Our objective in... BACKGROUND AND STUDY AIMSChildhood acquired chronic hepatitis B is associated with a significant lifetime risk of developing cirrhosis or hepatocellular... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 41 |
SubjectTerms | Adolescent Alanine Transaminase - blood Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Child Child, Preschool DNA, Viral - blood Female Genotype Guanine - adverse effects Guanine - analogs & derivatives Guanine - therapeutic use Hepatitis B e Antigens - blood Hepatitis B virus - genetics Hepatitis B virus - immunology Hepatitis B, Chronic - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Humans Male Retrospective Studies Treatment Outcome |
Title | Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22980589 https://search.proquest.com/docview/1040995577 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBZtFkovpe9uX6jQW1CwlNiyj0nZJW13s4c4kJ7MSJZDlq69OE6h_fUdyY94-4BtL8YILGPPp9E8vhkR8t6TJtBqrFnGlYcOShQxkAEwT0OodJRxCG1x8vkimK8mn9b--sCfd9UllRrpH3-sK_kfqeIYytVWyf6DZLtJcQDvUb54RQnj9VYythl9Dd-2ZY8vbmnibYG2YDwYfkcsO76GZefUTPO6IS4aiZZOXW13w1lHysr71uq0BNXvLbGBXVUWtotneSMavwRIwcVnLq6gPARilzYh7jY32GZwqIOYbXMWowPgckFfYFPsVQe8r2yOX-qOGh4u4co07OEmMGEZHi2BamScAhNe5DE0CeQNbTvuoUr0VOeE9zbhuifkb-q9jjRcjuByY1l5wnWpbd_Zb6W9uEhOV2dnSXyyju-SIyEj3x-Qo-nHz_NFu1GjZcK7RLej_P0y7d-dDmd8xA_Jg8ZroNMaAo_IHZM_JvfOG17EExJ3SKAdEmiR0RYJ1CKBOiTYYfx2apFAGyTQDgl0RjskPCWr05P4w5w152Wway6CiqWpyFCdalxwytgMqUxTmeJuZ8KxRreWh2j-mYm0hxporlTgWjkFni1JRENbjJ-RQV7k5gWhKuMcF3egua08VkGYKhRkasBXkQeZOCbv2l-ToD6ySSbITbHfJeje4_t9X8pj8rz-Z8l13TglESIK7TGWL2_x9Cty_wCq12RQlXvzBu2_Sr1t5PgT_-Rdsw |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Entecavir+treatment+of+children+2-16+years+of+age+with+chronic+hepatitis+B+infection&rft.jtitle=Arab+journal+of+gastroenterology&rft.au=Saadah%2C+Omar+I&rft.au=Sindi%2C+Haifa+H&rft.au=Bin-Talib%2C+Yagoub&rft.au=Al-Harthi%2C+Sameer&rft.date=2012-06-01&rft.eissn=2090-2387&rft.volume=13&rft.issue=2&rft.spage=41&rft.epage=44&rft_id=info:doi/10.1016%2Fj.ajg.2012.04.001&rft.externalDBID=NO_FULL_TEXT |